These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 1742754)

  • 41. [Prevention by naloxone of adverse effects of epidural morphine analgesia for cancer pain].
    Vedrenne JB; Esteve M; Guillaume A
    Ann Fr Anesth Reanim; 1991; 10(2):98-103. PubMed ID: 2058846
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of dopamine receptors in the dual effect of naloxone on quinpirole-induced yawning in morphine pretreated rats.
    Zharkovsky A; Moisio J; Kivastik T; Ahtee L
    Naunyn Schmiedebergs Arch Pharmacol; 1993 May; 347(5):478-82. PubMed ID: 8100615
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome.
    Reuter I; Ellis CM; Ray Chaudhuri K
    Acta Neurol Scand; 1999 Sep; 100(3):163-7. PubMed ID: 10478579
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Apomorphine test in de novo Parkinson's disease.
    Bonuccelli U; Piccini P; Del Dotto P; Pavese N; D'Antonio P; Muratorio A
    Funct Neurol; 1992; 7(4):295-8. PubMed ID: 1427361
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Blood pressure effects of apomorphine and domperidone in parkinsonism.
    Pollak P; Mallaret M; Gaio JM; Hommel M; Perret J
    Adv Neurol; 1987; 45():263-6. PubMed ID: 3548261
    [No Abstract]   [Full Text] [Related]  

  • 46. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease.
    Dewey RB; Maraganore DM; Ahlskog JE; Matsumoto JY
    Mov Disord; 1998 Sep; 13(5):782-7. PubMed ID: 9756146
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease.
    Factor SA
    Neurology; 2004 Mar; 62(6 Suppl 4):S12-7. PubMed ID: 15037666
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 10 questions about using apomorphine for Parkinson disease.
    Dewey RB
    Neurologist; 2005 May; 11(3):190-2. PubMed ID: 15860144
    [No Abstract]   [Full Text] [Related]  

  • 50. Apomorphine-subcutaneous--Bertek/Britannia.
    Drugs R D; 2004; 5(4):211-2. PubMed ID: 15230626
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease.
    Corsini GU; Del Zompo M; Gessa GL; Mangoni A
    Lancet; 1979 May; 1(8123):954-6. PubMed ID: 87620
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of naloxone on normal human sleep.
    Sitaram N; Gillin JC
    Brain Res; 1982 Jul; 244(2):387-92. PubMed ID: 6288191
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease.
    Di Rosa AE; Epifanio A; Antonini A; Stocchi F; Martino G; Di Blasi L; Tetto A; Basile G; Imbesi D; La Spina P; Di Raimondo G; Morgante L
    Neurol Sci; 2003 Oct; 24(3):174-5. PubMed ID: 14598073
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study.
    Ostergaard L; Werdelin L; Odin P; Lindvall O; Dupont E; Christensen PB; Boisen E; Jensen NB; Ingwersen SH; Schmiegelow M
    J Neurol Neurosurg Psychiatry; 1995 Jun; 58(6):681-7. PubMed ID: 7608665
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gastric relaxation and vomiting by apomorphine, morphine and fentanyl in the conscious dog.
    Lefebvre RA; Willems JL; Bogaert MG
    Eur J Pharmacol; 1981 Jan; 69(2):139-45. PubMed ID: 7202514
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase IIa randomized double-blind, placebo-controlled study of inhaled apomorphine as acute challenge for rescuing 'off' periods in patients with established Parkinson's disease.
    Grosset KA; Malek N; Morgan F; Grosset DG
    Eur J Neurol; 2013 Nov; 20(11):1445-50. PubMed ID: 23350812
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Video assessment of yawning induced by sublingual apomorphine in migraine.
    Del Bene E; Poggioni M; De Tommasi F
    Headache; 1994 Oct; 34(9):536-8. PubMed ID: 8002329
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications.
    Verhagen Metman L; Locatelli ER; Bravi D; Mouradian MM; Chase TN
    Neurology; 1997 Feb; 48(2):369-72. PubMed ID: 9040723
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Domperidone is superior to ondansetron in acute apomorphine challenge in previously untreated parkinsonian patients - A double blind study.
    Arnold G; Schwarz J; Macher C; Oertel WH
    Parkinsonism Relat Disord; 1997 Dec; 3(4):191-3. PubMed ID: 18591075
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events.
    Dewey RB; Hutton JT; LeWitt PA; Factor SA
    Arch Neurol; 2001 Sep; 58(9):1385-92. PubMed ID: 11559309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.